Johnson & Johnson Innovation - Jjdc is an investment fund managing more than $978 million ran by Sergio Calvo-regueros. There are currently 21 companies in Mr. Calvo-regueros’s portfolio. The largest investments include Fate Therapeutics Inc and Arrowhead Pharmaceuticals, together worth $563 million.
As of 27th July 2021, Johnson & Johnson Innovation - Jjdc’s top holding is 3,379,064 shares of Fate Therapeutics Inc currently worth over $293 million and making up 30.0% of the portfolio value.
Relative to the number of outstanding shares of Fate Therapeutics Inc, Johnson & Johnson Innovation - Jjdc owns more than approximately 0.1% of the company.
In addition, the fund holds 3,260,869 shares of Arrowhead Pharmaceuticals worth $270 million, whose value fell 15.3% in the past six months.
The third-largest holding is Protagonist Therapeutics Inc worth $110 million and the next is Cvrx, Inc. worth $97.9 million, with 3,495,575 shares owned.
Currently, Johnson & Johnson Innovation - Jjdc's portfolio is worth at least $978 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Johnson & Johnson Innovation - Jjdc office and employees reside in New Brunswick, New Jersey. According to the last 13-F report filed with the SEC, Sergio Calvo-regueros serves as the Assistant Treasurer at Johnson & Johnson Innovation - Jjdc.
In the most recent 13F filing, Johnson & Johnson Innovation - Jjdc revealed that it had opened a new position in
Cvrx, Inc. and bought 3,495,575 shares worth $97.9 million.
On the other hand, Sergio Calvo-regueros disclosed a decreased stake in Senseonics Inc by 0.9%.
This leaves the value of the investment at $210 thousand and 54,621 shares.
The two most similar investment funds to Johnson & Johnson Innovation - Jjdc are Blueshift Asset Management and Ledyard National Bank. They manage $978 million and $977 million respectively.
Johnson & Johnson Innovation - Jjdc’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 85.9% of
the total portfolio value.
The fund focuses on investments in the United States as
61.9% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
10% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.89 billion.
These positions were updated on August 3rd based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Fate Therapeutics Inc |
No change
3,379,064
|
$293,269,000 | 29.98% |
| Arrowhead Pharmaceuticals Inc. |
No change
3,260,869
|
$270,065,000 | 27.61% |
| Protagonist Therapeutics Inc |
No change
2,449,183
|
$109,919,000 | 11.24% |
| Cvrx, Inc. |
Opened
3,495,575
|
$97,876,000 | 10.01% |
| Legend Biotech Corp |
No change
1,629,173
|
$66,878,000 | 6.84% |
| MeiraGTx Holdings plc |
No change
2,898,550
|
$44,928,000 | 4.59% |
| Fusion Pharmaceuticals Inc. |
No change
3,670,516
|
$29,658,000 | 3.03% |
| Vor Biopharma, Inc. |
No change
1,074,658
|
$20,042,000 | 2.05% |
| BiomX Inc |
No change
2,133,402
|
$11,648,000 | 1.19% |
| Therapeutics Acquisition Cor |
Opened
1,000,000
|
$10,274,000 | 1.05% |
| Adicet Bio, Inc. |
No change
728,944
|
$7,501,000 | 0.77% |
| PhaseBio Pharmaceuticals, Inc. |
No change
1,607,044
|
$5,978,000 | 0.61% |
| Aldeyra Therapeutics Inc |
No change
394,834
|
$4,473,000 | 0.46% |
| Castlight Health Inc |
No change
811,295
|
$2,134,000 | 0.22% |
| Neuropace, Inc. |
Opened
55,435
|
$1,319,000 | 0.13% |
| Zymergen Inc. |
Opened
16,553
|
$662,000 | 0.07% |
| TRACON Pharmaceuticals Inc |
No change
84,003
|
$545,000 | 0.06% |
| Catalyst Biosciences Inc |
No change
66,951
|
$290,000 | 0.03% |
| Graybug Vision, Inc. |
No change
49,547
|
$269,000 | 0.03% |
| Pulmonx Corp |
No change
5,639
|
$249,000 | 0.03% |
| Senseonics Holdings Inc |
88.90%
54,621
|
$210,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 21 holdings | |||